Mette Bjerre

The association between circulating adiponectin levels, lung function and adiposity in subjects from the general population; data from the Akershus Sleep Apnea Project

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Nina F Caspersen, Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • ,
  • Helge Røsjø, Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • ,
  • Allan Flyvbjerg, Steno Diabetes Center Copenhagen (SDCC), the Capital Region of Denmark and University of Copenhagen, Copenhagen, Denmark.
  • ,
  • Mette Bjerre
  • Anna Randby, Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Clinical Molecular Biology (EpiGen), Medical Division, Akershus University Hospital, Lørenskog, Norway. Electronic address: Vessela.N.Kristensen@rr-research.no.
  • ,
  • Harald Hrubos-Strøm, Department of Otorhinolaryngology, Division of Surgery, Akershus University Hospital, Lørenskog, Norway.
  • ,
  • Torbjørn Omland, Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • ,
  • Gunnar Einvik, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. gunnar.einvik@medisin.uio.no.

BACKGROUND: Circulating adiponectin (ADPN) levels are inversely associated with disease severity in patients with chronic obstructive pulmonary disease (COPD), while studies assessing the relationship between ADPN and lung function in subjects from the general population have shown diverging results. Accordingly, we hypothesized that ADPN would be associated with lung function in a population-based sample and tested how abdominal adiposity, metabolic syndrome, and systemic inflammation influenced this association.

METHODS: We measured total ADPN in serum, forced vital capacity (FVC) and forced expiratory volume during the 1st second (FEV1) in 529 participants (median 50 years, 54.6% males) recruited from the general population. We assessed the association between ADPN and lung function by multivariate linear regression analyses and adjusted for age, gender, height, smoking habits, weight, body mass index, waist-hip ratio, metabolic syndrome, obstructive sleep apnoea (OSA) and C-reactive protein.

RESULTS: The median (interquartile range) level of serum ADPN was 7.6 (5.4-10.4) mg/L. ADPN levels were positively associated with FVC % of predicted (beta 3.4 per SD adiponectin, p < 0.001)) in univariate linear regression analysis, but the association was attenuated in multivariate analysis (standardized beta 0.03, p = 0.573)). Among co-variates only WHR significantly attenuated the relationship. ADPN levels were also associated with FEV1% of predicted in bivariate analysis that adjusted for smoking (beta 1.4, p = 0.042)), but this association was attenuated and no longer significant in multivariate analysis (standardized beta -0.06, p = 0.254)).

CONCLUSION: In this population-based sample no association between ADPN and lung function was evident after adjustment for covariates related to adiposity.

OriginalsprogEngelsk
TidsskriftB M C Pulmonary Medicine
Vol/bind18
Nummer1
Sider (fra-til)54
ISSN1471-2466
DOI
StatusUdgivet - 2 apr. 2018

Se relationer på Aarhus Universitet Citationsformater

ID: 125896713